PRINCETON, NJ – A delegation representing more than 20 New Jersey organizations, including top life sciences companies, universities, trade associations, State government and Choose New Jersey, Inc. will showcase New Jersey’s assets and resources for biotechnology companies at the New Jersey Pavilion (Booth #1737) at BIO International 2017, June 19-22 (2017) in San Diego, California.
During the world’s largest biotechnology conference, members of the New Jersey delegation will be holding business meetings with executives representing companies in North America, Europe and Asia interested in learning more about the benefits of a New Jersey location. Executives also will engage in informal discussions with New Jersey’s top life sciences leaders at the Seventh Annual Choose New Jersey Reception the evening of Monday, June 19 to kick off BIO 2017.
“BIO International is an incredible venue to showcase New Jersey’s wealth of biotechnology resources to the world,” said Michele Brown, President and CEO of Choose New Jersey, Inc. “We are honored to travel with our delegation to San Diego to bring our message to the international life sciences community: New Jersey can support your company at every stage of growth. We offer vibrant life sciences campuses that offer quality lab space, along with access to new funding sources. As you can see from our delegation, we provide opportunities for partnering with some of the world’s leading biopharmaceutical companies and research universities, of which we are truly proud. And, as the world knows, our diverse and highly educated talent pool is our top selling point, and it simply can’t be beat.”
Home to the headquarters or major facilities of 13 of the top 20 biopharmaceutical companies, biotechnology companies that settle in New Jersey have access to high quality lab space, including incubator, intermediate and larger stand-alone space; attractive incentives, including incentives specially created to support start-up and early-stage ventures; access to venture capital, as well as collaborations with leading biopharmaceutical companies and research universities. Biotechnology companies in New Jersey also have access to an exceptional workforce that makes it easy to recruit top talent, including talent that has deep experience in biopharmaceutical commercialization.
Choose New Jersey is partnering with BioNJ, the Healthcare Institute of New Jersey (HINJ), the New Jersey Business Action Center and the New Jersey Economic Development Authority (NJEDA) to sponsor the 1,500-square-foot New Jersey Pavilion at BIO 2017 in San Diego.
Members of the delegation who will be represented in the Pavilion include life sciences companies Novartis, Ferring Pharmaceuticals, Janssen Pharmaceutical Companies of Johnson & Johnson, Celgene, Helsinn and Evotec.
Universities, researchers, and academic medical centers include Princeton University, Rutgers University, New Jersey Institute of Technology (NJIT), New Jersey Innovation Institute (NJII), Rowan University, Stevens Institute of Technology and Hackensack Meridian Health/Hackensack University Medical Center.
Real estate developers of first class co-working, collaboration, lab and office space include NJEDA’s Commercialization Center for Innovative Technologies, DEVCO’s the Hub @ New Brunswick Station, Bell Works and ON3. Professional services organizations represented in the Pavilion include Sills Cummis & Gross P.C., Cushman & Wakefield, CBRE Life Sciences Group, JLL, PwC, Accenture, and BioJump.
“New Jersey’s dynamic life sciences ecosystem – including large and small companies, incubators and lab space, mentoring and partnering opportunities and funding at every stage of development – has helped make New Jersey a leading biopharma hub,” said Debbie Hart, President and CEO of BioNJ. “We’re eager to showcase our companies, research institutions and supporting organizations at BIO and look forward to demonstrating why the Garden State is at the forefront of new and sustained medical innovation.”
“As the lead sponsor of its reception at the BIO International Convention in San Diego, HINJ is pleased to partners, once again, with Choose New Jersey in its efforts to promote the Garden State’s world-class life sciences innovation ecosystem,” said Dean J. Paranicas, President and Chief Executive Officer, HealthCare Institute of New Jersey (HINJ).
For more information about growing your biopharmaceutical company in New Jersey, visit the New Jersey Pavilion (Booth #1737) at the San Diego Convention Center (adjacent to the Business Forum at BIO International 2017,) call Choose New Jersey at 609-297-2200 or visit www.choosenj.com.
For the Media: If you would like to request an interview with Michele Brown, President and CEO of Choose New Jersey, Debbie Hart, President and CEO of BioNJ and/or other representatives of the New Jersey delegation at BIO International, please contact Communications Manager, Susan White at [email protected] or 609-297-2198.
About Choose New Jersey, Inc.
Choose New Jersey, Inc. is a privately funded 501(c)(3) corporation charged with encouraging and nurturing economic growth throughout New Jersey with a focus on its urban centers. Through marketing, business attraction and lead generation activities, Choose New Jersey markets New Jersey as a premiere business location to both domestic and international businesses. Choose New Jersey is a member of the Partnership for Action (PFA), which is led by Lt. Governor Kim Guadagno and also includes the New Jersey Business Action Center, the New Jersey Economic Development Authority and the Office of the Secretary of Higher Education. For more information, visit www.choosenj.com.
BioNJ is a network of over 400 Members representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
Founded in 1997, the Healthcare Institute of New Jersey (HINJ) serves as the voice for the state’s life sciences industry. HINJ seeks to expand patient access to the most innovative biopharmaceuticals and medical devices and promote awareness of the industry’s impact on New Jersey’s quality of life and economic well-being. To learn more, please visit HINJ at www.hinj.org.